About us

Keith joined as Chairman of the Board in June 2026. He has 30 years of biopharma industry experience leading companies and driving commercial strategies. Keith previously served as Chairman and CEO of Unity Biotechnology. Prior to joining Unity, he served as co-founder, president and CEO of Kythera Biopharmaceuticals from its founding in 2005 through its acquisition by Allergan plc in 2015. Before Kythera, Keith spent 13 years at Amgen, serving as senior Vice President and General Manager of Amgen Europe, where he oversaw commercial operations across 28 countries. During his tenure at Amgen, he ran the company’s manufacturing operations in Europe, established Amgen’s presence in inflammation, served as head of information management, and held leadership roles in sales and marketing, engineering, operations, and finance. Keith has also served as an independent director for Spanish biotech Sanifit SA, Anacor Pharmaceuticals, Affymax, and ARYx Therapeutics, and was a venture partner with ARCH Venture Partners.

Keith began his career as an officer in the Civil Engineer Corps of the U.S. Navy. He earned a Master of Business Administration from the Anderson School of Management at the University of California, Los Angeles, holds a Master of Science in mechanical engineering from the University of California, Berkeley, a B.A. in history from the University of Maryland, College Park, and a BSc in engineering from the University of California, Los Angeles.

Keith is currently Chairman of Arcutis Biotherapeutics and sits on the board of Intuitive Surgical.

Mark joined the Board of Antag Therapeutics in June 2023. He has developed discovery and development programs at several biopharma companies, resulting in the creation of blockbuster drugs, such as Celebrex and Linzess from his research labs. Notably, he is the primary inventor of Linzess, the first all-natural amino acid oral peptide. Currently, Mark serves as a Director of the Board at Ironwood Pharmaceuticals, where he previously held the position of President, and he also served as President of Cyclerion.

Additionally, he is a venture partner at Iaso Ventures, responsible for investments in therapeutics. In addition to his role at Antag, Mark is on the board of Sea Pharmaceuticals and chairs the Scientific Advisory Boards (SABs) for Scaffold Therapeutics and Wild Bio. His previous board memberships include Science Exchange and the Foundation for Research at the Medical University of South Carolina. Mark holds a PhD in Cell Biology from Wake Forest University School of Medicine and a BS from University of South Alabama.

Jørgen joined the Board of Antag Therapeutics in November 2024. He brings 20 years of experience in the pharmaceutical industry and is currently a Senior Partner at Novo Holdings.

He has held executive R&D roles at Lundbeck, Zealand Pharma, Merck, and Novo Nordisk, and was a co-founder of Zealand Pharma, where he led the company through to exit.

Jørgen currently serves on the Boards of Acesion Pharma, Engimmune Therapeutics, Breye Therapeutics, Hemab Therapeutics, and Tribune Therapeutics.

He holds an MD and a PhD in Pharmacology from the University of Copenhagen, and an MBA from the Technical University of Denmark.

Amit joined the Board of Antag Therapeutics in November 2024. He is a board-certified equivalent plastic surgeon specialising in microsurgical cancer reconstruction and is currently a Principal at SR One Capital Management.

Prior to joining SR One, he held various roles at GlaxoSmithKline across late-phase clinical development, global medical affairs, and early pipeline commercial strategy.

Amit sits on the venture capital panel of the BioInnovation Institute, Novo Nordisk’s international life sciences incubator, and serves on the Boards of ADARx Pharmaceuticals, Asceneuron, Codify Therapeutics, HotSpot Therapeutics, and River Renal.

He holds an MD from the University of Cambridge.